The threonine and serine protein kinase AKT plays a major role in inhibiting apoptosis in a number of malignant cell types including prostate and breast carcinoma. Activation of AKT is a complex process involving translocation to the plasma membrane and phosphorylation of serine and threonine amino-acid residues. We now report that the novel compound 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), induces apoptosis in breast and prostate carcinoma cells and inhibits AKT activity in these cells. Overexpression of a constitutively activated AKT inhibits 3-Cl-AHPC-mediated apoptosis. Decrease in AKT activity occurs through 3-Cl-AHPC inhibition of phosphatidylinositol 3 kinase (PI3-K) activity. 3-Cl-AHPC inhibits PI3-K activity by enhancing epidermal growth factor receptor (EGFR) proteolysis and thus inhibiting EGFR association with the p85 subunit of PI3-K. 3-Cl-AHPCmediated decrease in PI3-K activity results in the reduced synthesis of phosphatidylinositol 3,4 bisphosphate and phosphatidylinositol 3,4,5 triphosphate with the subsequent inhibition of integrin-linked kinase activity and serine-473 phosphorylation of AKT. Overexpression of EGFR results in increased AKT activity and inhibition of 3-Cl-AHPC-mediated decrease in AKT activation, AKT activity and 3-Cl-AHPC-mediated apoptosis. Inhibition of AKT activity by this compound results in the inability of AKT to phosphorylate and inactivate the proapoptotic forkhead transcription factor.
The threonine and serine protein kinase AKT plays a major role in inhibiting apoptosis in a number of malignant cell types including prostate and breast carcinoma. Activation of AKT is a complex process involving translocation to the plasma membrane and phosphorylation of serine and threonine amino-acid residues. We now report that the novel compound 4- [3- (1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid , induces apoptosis in breast and prostate carcinoma cells and inhibits AKT activity in these cells. Overexpression of a constitutively activated AKT inhibits 3-Cl-AHPC-mediated apoptosis. Decrease in AKT activity occurs through 3-Cl-AHPC inhibition of phosphatidylinositol 3 kinase (PI3-K) activity. 3-Cl-AHPC inhibits PI3-K activity by enhancing epidermal growth factor receptor (EGFR) proteolysis and thus inhibiting EGFR association with the p85 subunit of PI3-K. 3-Cl-AHPCmediated decrease in PI3-K activity results in the reduced synthesis of phosphatidylinositol 3,4 bisphosphate and phosphatidylinositol 3,4,5 triphosphate with the subsequent inhibition of integrin-linked kinase activity and serine-473 phosphorylation of AKT. Overexpression of EGFR results in increased AKT activity and inhibition of 3-Cl-AHPC-mediated decrease in AKT activation, AKT activity and 3-Cl-AHPC-mediated apoptosis. Inhibition of
Introduction
A number of studies have demonstrated that the protein kinase AKT (protein kinase B) plays a major role in the survival of cells under a variety of conditions (Datta et al., 1999 and refs within) . AKT blocks the induction of apoptosis by a large number of stimuli; these include DNA damage, growth factor withdrawal, ultraviolet irradiation as well as anti-Fas antibody and transforming growth factor b-mediated apoptosis Kennedy et al., 1997; Kulik et al., 1997; Philpott et al., 1997; Chen et al., 1998; Hausler et al., 1998) . Many of these studies have utilized transfection with either constitutively active AKT alleles or the use of dominant-negative alleles of AKT; while the studies utilizing dominant-negative alleles have been criticized for the potential nonspecificity of the vectors, these studies have all supported a vital role for AKT in cell survival.
AKT contains a central kinase domain with specificity for serine or threonine residues in substrate proteins. A number of proteins have been identified that possessed these or similar consensus phosphorylation sites (Datta et al., 1999) . The proapoptotic proteins Bad, forkhead transcription factor (FHKR) and human caspase-9 have been found to be substrates of AKT and their phosphorylation by AKT results in the inhibition of their functions and thus, their ability to induce apoptosis Cardone et al., 1998; Brunet et al., 1999; Lazebnik, 2000) . Recently, the ability of AKT to activate antiapoptotic proteins has also been demonstrated. Exposure of normal human skin fibroblasts as well as rat fibroblast -like synoviocytes to platelet-derived growth factor results in AKT activation of IkB kinase, phosphorylation and degradation of the NF-kB repressor IkBa and translocation of NF-kB to the nucleus where it enhances the expression of a number of antiapoptotic proteins (Khwaja, 1999; Romashkova and Makarov, 1999) .
AKT activation inhibits apoptosis in breast and prostate carcinoma cells whereas inhibition of its activity results in the induction of apoptosis (Davies et al., 1999; Hsu et al., 2000) . In addition, ecoptic overexpression in breast carcinoma cells of the tumor suppressor gene PTEN, which inhibits the phosphorylation of the activating residues of AKT, results in apoptosis induction (Ghosh et al., 1999) . We and others have previously demonstrated that the retinoid nuclear receptor (RAR) g selective retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437) induces apoptosis in prostate and breast carcinoma cells (Charpenter et al., 1995; Shao et al., 1995; Liang et al., 1999) . In this study, we demonstrate that the novel compound 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), which does not transactivate the RARs, inhibits AKT activation followed by the induction of apoptosis in breast and prostate carcinoma cells. Introduction of a constitutively activated AKT blocks 3-Cl-AHPC-mediated apoptosis. Since AKT has been shown to play an important role in the resistance of breast and prostate carcinoma cells to apoptosis, we examined the pathway by which 3-Cl-AHPC inhibits AKT activation in these cells. We have found that 3-Cl-AHPC exposure results in the inhibition of PI3-K activity and AKT activation. While not modulating Ras, Cdc42, Rho or Rac binding to the phosphatidylinositol 3 kinase (PI3-K) p110 subunit, 3-Cl-AHPC enhances the ubiquitination and proteolysis of the epidermal growth factor receptor (EGFR) and inhibits subsequent EGFR binding to the PI3-K p85 subunit. That this 3-Cl-AHPC-mediated EGFR enhanced proteolysis is important in 3-Cl-AHPC-mediated apoptosis is supported by the observation that EGFR overexpression activates AKT and inhibits 3-Cl-AHPC-mediated apoptosis.
Results

3-
Cl-AHPC inhibits AKT activity, serine-473 phosphorylation and induces apoptosis 3-Cl-AHPC-mediated apoptosis of the prostate and breast carcinoma cell lines was noted within 48 h of exposure (Table 1) . Inhibition as well as activation of AKT has been seen prior to and following apoptosis induction (Tang et al., 2001) . We therefore, assessed the effect of 3-Cl-AHPC on AKT activity in this period. Exposure of DU145, LNCaP, PC-3 and MDA-MB-468 cells to 1 mM 3-Cl-AHPC for varying times resulted in the inhibition of AKT activity in all of the cell types (Figures 1a and b) . AKT activity was inhibited by 50-65% in the LNCaP, PC-3 and MDA-MB-468 cells at 24 h following 3-Cl-AHPC exposure while a 48 h exposure was required to achieve 75% inhibition of AKT in DU145 cell (Figures 1a and b Figure 1 3-Cl-AHPC inhibition of AKT activity and AKT serine-473 phosphorylation. Cells were grown as described in Materials and methods and exposed to 1 mM 3-Cl-AHPC for varying times. AKT activity and AKT serine-473 phosphorylation was assessed as described in Materials and methods. Apoptosis was assessed as described in Materials and methods. The results represent the mean and standard deviations of three independent determinations. Apoptosis was assessed using acridine orange staining as described in Materials and methods. A total of 200 cells were assessed 3-Cl-AHPC inhibition of AKT activity L Farhana et al levels were significantly lower in DU145 cells; thus even a small inhibition of AKT activity in these cells may result in enhanced apoptosis ( Figure 1 and Table 1 ). Activation of AKT requires the phosphorylation of a number of crucial sites including threonine-308 and serine-473 (Andjelkovic et al, 1997; Toker, 2000) ; phosphorylation of these specific amino acids appears to be essential for the activation of AKT (Chan et al., 1999) . Since 3-Cl-AHPC exposure resulted in the inhibition of AKT activity, we examined the effect of 3-Cl-AHPC on the phosphorylation of these amino-acid residues. 3-Cl-AHPC inhibited AKT serine-473 phosphorylation in the DU145, PC-3, LNCaP and MDA-MB-468 cells with a maximum inhibition of 60-80% noted in the DU145 and LNCaP cell lines and 50-55% in the PC-3 and MDA-MB-468 cell lines at 48 h ( Figures  1c and d) . The data in Figure 1 demonstrate that treatments with 3-Cl-AHPC for 24 h results in inhibition of serine-473 phosphorylation of AKT in all of the cell lines tested. The loss of AKT phosphorylation results in the loss of AKT activation following 3-Cl-AHPC treatments for 24 h in all of the cell lines with the exception of DU145 cells. A 70% inhibition of phospho-AKT levels but only a 10% inhibition of AKT activity is noted in DU145 cells following 24 h 3-Cl-AHPC exposure; 80% AKT inhibition is noted at 48 h in these cells. Whether other pathways may be involved in AKT activation in these cells and which are inhibited by 3-Cl-AHPC are unclear. Significant apoptosis, however, was noted in all the cell lines following treatments with 3-Cl-AHPC for 48 h (see Table 1 ). Thus, 3-Cl-AHPC treatment results in inhibition of AKT phosphorylation and AKT activity and the induction of apoptosis in the prostate and breast carcinoma cell lines. 3-Cl-AHPC had no effect on AKT threonine-308 phosphorylation in any of the cell lines (data not shown).
Expression of a constitutively activated AKT inhibits 3-Cl-AHPC-mediated apoptosis
In order to demonstrate that 3-Cl-AHPC inhibition of AKT activation plays an important role in 3-Cl-AHPCmediated apoptosis, we transiently expressed a myristylated, constitutively activated AKT mutant form. This AKT variant is active even in the absence of stimuli required for PI3-K activation (Kohn et al., 1996; Crowder and Freeman, 1998) . Expression of this mutated AKT in LNCaP and MDA-MB-468 cells resulted in the resistance to 3-Cl-AHPC-mediated apoptosis (Figure 2 ).
Integrin-linked kinase (ILK) activity is inhibited in 3-Cl-AHPC exposed cells
The identification of the kinase(s) responsible for serine-473 phosphorylation is still unclear and several candidates have been suggested (Tang et al., 2001) ; several studies have, however, identified ILK as a potential candidate (Delcommenne et al., 1998; Persad et al., 2000) . We therefore examined ILK activity in prostate and breast carcinoma cells following exposure to 3-Cl- 3-Cl-AHPC inhibits PI3-K activity PI3-K has been shown to activate PDK-1, ILK and AKT through the generation of phosphatidylinositol bisphosphate (PtdIns (3,4)P 2 ) and phosphatidylinositol triphosphate (PtdIns (3,4,5)P 3 ) (Datta et al., 1999; Toker, 2000) . Since 3-Cl-AHPC exposure resulted in a decrease in ILK and AKT activities, we examined the effect of 3-Cl-AHPC on PI3-K activity. 3-Cl-AHPC inhibited PI3-K activity in all four cell lines within 24 h (Figures 4a and b ). PI3-K activity was inhibited maximally by 60 percent in the DU145 and LNCaP cells and by 40 percent in the PC-3 cells at 24 h. In contrast, maximum inhibition of PI3-K activity in MDA-MB-468 cells required 48 h incubation with 3-Cl-AHPC (Figures 4a and b) . No change in PI3-K p85 subunit levels was noted following exposure to 3-Cl-AHPC.
3-C-AHPC inhibits EGFR binding to p85
Activation of PI3-K is complex and can involve the binding of a number of mediators to either the p110 or 
MDA-MB-468
Figure 2 Expression of a constitutively activated AKT of inhibits 3-Cl-AHPC-mediated apoptosis. Cells were stably transfected with control plasmid pcDNA3 and plasmid expressing the myristylatedAkt-pcDNA3 under the CMV promoter. Apoptosis was determined using acridine orange staining as described in Materials and methods. A total of 400 cells were assessed 3-Cl-AHPC inhibition of AKT activity L Farhana et al p85 subunits (Chan et al., 1999; Datta et al., 1999) . Binding of activated Ras to the p110 subunit, Rac or Cdc 42 to the p85 subunit or the binding of specific phosphotyrosines to the p85 subunit have been associated with the activation of PI3-K (Chan et al., 1999; Datta et al., 1999) . 3-Cl-AHPC did not inhibit the binding of these proteins to the p110 or p85 subunit. Recent studies have shown that EGFR can directly bind to and phosphorylate the p85 subunit of PI3-K resulting in PI3-K activation (Soler et al., 1994; Tiganis et al., 1999; Imukai et al., 2001) . EGFR expression is significantly increased in androgen-independent prostate cancer cells and EGFR plays a significant role in the prognosis of prostate cancer (Gil-Diez de Medina et al., 1998; Schwartz et al., 1999; Agarwal, 2000) . In addition, MDA-MB-468 cells overexpress EGFR and the EGF can stimulate the growth of these cells (Balmer et al., 2001) . We therefore, examined the effect of 3-Cl-AHPC exposure on the association of p85 with EGFR. 3-Cl-AHPC markedly inhibited the association of EGFR with the p85 subunit in all of the cell lines and decreased total EGFR levels ( Figure 5a ). The 3-Cl-AHPCmediated decrease in EGFR levels was blocked by the proteasome inhibitor LLnL, indicating that 3-Cl-AHPC enhanced EGFR proteolysis through the proteasome pathway ( Figure 5b ). In addition, LLnL inhibited 3-Cl-AHPC-mediated apoptosis ( Figure 5c ). We assessed whether 3-Cl-AHPC enhanced EGFR ubiquitination. 3-Cl-AHPC exposure resulted in increased EGFR ubiquitination ( Figure 6a ). The anchorage protein c-Cbl has been found to associate with a number of receptor proteins including EGFR and mediates EGFR proteolysis Yokouch et al., 1999; Sook et al., 2002) . Ligand activation of EGFR results in the Yokouch et al., 1999; Sook et al., 2002) . We found that c-Cbl associated with EGFR in the MDA-MB-468 as well as the other cell types (Figure 6b and data not shown). 3-Cl-AHPC exposure resulted in the decrease in total c-Cbl levels along with the decrease in EGFR levels but an increase in phosphotyrosine c-Cbl and an increase in c-Cbl associated with phosphotyrosine EGFR (Figure 6b) . A constant amount of c-Cbl was found associated with the decreasing EGFR levels ( Figure 6b) ; thus the ratio of the levels of c-Cbl to EGFR was constantly increasing. Loss of EGFR p85 binding is associated with an increase in p85 associated tyrosine-phosphorylated proteins (Figure 6c) . Rameh et al. (1995) previously reported that inhibition of PI3-K results in enhanced binding of tyrosine-phosphorylated proteins to p85 secondary to the decreased levels of PtdIns (3,4,5)P 3 and PtdIns (3,4)P 2 levels and their binding to p85. PtdIns (3,4,5)P 3 and PtdIns (3,4)P 2 inhibit the binding of these yet to be identified tyrosine-phosphorylated proteins to p85 and the enhanced binding of these proteins results in the inhibition of PI3-K activity (Rameh et al., 1995) .
EGFR enhanced expression results in resistance to 3-Cl-AHPC-mediated apoptosis
It is not possible to assess whether 3-Cl-AHPC blocks EGF-mediated growth or induction in these cells since these studies require very low serum concentrations to demonstrate the EGF effect on growth and AKT stimulation. 3-Cl-AHPC is toxic at these low serum concentrations due to its decreased protein binding and enhanced access to the cells. We therefore determined the importance of EGFR activation of AKT and its degradation by 3-Cl-AHPC by assessing the effect of EGFR overexpression on AKT activation. Even a minimally enhanced EGFR expression of 1.5-2-fold resulted in inhibition of 3-Cl-AHPC downregulation of EGFR expression, and enhanced AKT serine-473 phosphorylation as well as AKT activity in both the presence and absence of 3-Cl-AHPC (Figures 7a-c) . In addition, EGFR overexpression inhibits 3-Cl-AHPCmediated apoptosis (Figure 7d ). These results would suggest that 3-Cl-AHPC-mediated downregulation of EGFR expression plays an important role in 3-Cl-AHPC inhibition of AKT activation and its apoptosis induction.
3-Cl-AHPC inhibits AKT-mediated phosphorylation of FKHR
AKT kinase phosphorylates a number of proapoptotic substrates resulting in their inactivation (Datta et al., 1999) . AKT kinase phosphorylation of FKHR has been shown to result in sequestration of FKHR in the cytoplasm (Datta et al., 1999) . Since 3-Cl-AHPC inhibited AKT kinase activity, we examined 3-Cl- (Figures 8a and b) . FKHR expression could not be detected in the DU145 cells. Wan et al. (2001) have recently reported that the RARas elective retinoid CD437/AHPN inhibits AKT activation in 3T3 fibroblasts and that overexpression of acidic fibroblast growth factor blocks CD437/AHPN inhibition of AKT activation. We have now demonstrated that the novel CD437/AHPN analog 3-Cl-AHPC, which does not transactivate the RARs inhibits AKT activation in breast and prostate carcinoma cells through its enhanced proteasome-mediated proteolysis of EGFR. Overexpression of either EGFR or AKT blocks 3-Cl-AHPC-mediated apoptosis. Furthermore, 3-Cl-AHPC enhanced proteolysis of EGFR is associated with a decrease in PI3-K, ILK and AKT activities. PI-3 kinase is an important activator of AKT. The PI-3 kinases are a family of ubiquitous signaling proteins that phosphorylate the 3-hydroxyl group of phosphatidylinositols. The Class 1 PI3-Ks are responsible for the synthesis of the intracellular PtdIns (3,4)P 2 and Ptdlns (3,4,5)P 3 (Domain and Waterfield, 1997) . The PI3-K-dependent synthesis of PtdIns (3,4)P 2 and PtdIns (3,4,5)P 3 results in their accumulation in the inner leaflet of the plasma membrane and the subsequent membrane localization and activation of proteins that specifically bind these phosphatidylinositols; this colocalization and activation of enzymes along with their substrates allows for enhanced signaling activity within the cell resulting in marked modulation of cell phenotype and proliferation (Pacold et al., 2000) . We have shown that 3-Cl-AHPC inhibits both AKT and ILK activities in addition to PI3-K in agreement with the proposed cascade of PI3-K activation of ILK and AKT. Class IA PI3-K is a heterodimer consisting of a 110 kDa (p110) catalytic subunit and a 85 kDa (p85) regulatory subunit (Pacold et al., 2000) . Activation of PI3-K can occur through the binding of Ras, Rac, Rho, Cdc42 or specific phosphotyrosine proteins to specific domains (Carpentier et al., 1990; Yamamoto et al., 1992; Joly et al., 1994; Kapeller et al., 1994; Levy-Toledano et al., 1994) . Binding of Ras to the p110 subunit, Rho, Rac or Cdc42 to the p85 subunit or specific phosphotyrosine proteins to the SH2 or SH3 domains of p85 can result in PI3-K activation (Sjolander et al., 1991; Zheng et al., 1994; RodriquezViciana et al., 1997; Chan et al., 1999; Rubio et al., 1999; Rebello and Ayllon, 2000) . The prostate and breast carcinoma cell lines examined in this study displayed binding of activated Ras, as well as Cdc42, Rho, Rac and EGFR to PI3-K; 3-Cl-AHPC did not modulate the binding of Ras, Rho, Cdc42 to PI3-K in any of the cell lines. However, 3-Cl-AHPC inhibited EGFR binding to p85 and also decreased total EGFR levels by enhancing EGFR proteolysis through the proteasome pathway. We found the c-Cbl anchorage protein associated with EGFR. c-Cbl has been found to not only enhance EGFR proteasome-mediated proteolysis but also that of a large number of activated protein tyrosine kinase receptors including the platelet-derived growth factor receptor, and the colony stimulating factor-1 receptor (Levkowitz et al., 1999; Zheng et al., 2000) . Further evidence in support of the importance of c-Cbl's role in negatively modulating the function of these receptor tyrosine protein kinases is derived from the recent observation that oncogenic forms of c-Cbl mediate acute transformation by blocking wild-type c-Cbl's ability to polyubiquitinate and enhance the proteolysis of these receptor tyrosine protein kinases (Zheng et al., 2000 and references within) . c-Cbl appears to perform the docking function of a E3 ligase complex as well as bind the E2 enzyme UbcH7 through the c-Cbl ring domain (Yokouch et al., 1999) . This allows for the c-Cblmediated ubiquitination of these receptor tyrosine protein kinases and their subsequent proteolysis through the proteasome pathway Yokouch et al., 1999) . Overexpression of EGFR in MDA-MB-468 and LNCaP cells results in the failure of 3-Cl-AHPC to significantly downregulate EGFR expression, persistent activation of AKT despite the presence of 3-Cl-AHPC and resistance to 3-Cl-AHPCmediated apoptosis in these cells. These results strongly suggest that 3-Cl-AHPC inhibition of EGFR expression is important in 3-Cl-AHPC-mediated apoptosis.
Discussion
PI3-K activation and the subsequent accumulation of PtdIns (3,5)P 2 and PtdIns (3,4,5)P 3 results in the translocation of AKT to the plasma membrane where phosphorylation of AKT at a number of sites is required for AKT activation (Hannigan et al., 1996; Chan et al., 1999; Datta et al., 1999) . Alessi et al. (1997a, b) identified four AKT sites (serine-124, threonine-308, threonine-450 and serine-473), which are phosphorylated in vivo. While serine-124 and threonine-450 appear to be constitutively phosphorylated, threonine-308 and serine-473 phosphorylation occurs after exposure of the cells to external stimuli and AKT translocates to the plasma membrane (Datta et al., 1999; Tang et al., 2001) . Phosphorylation of threonine-308 and serine-473 has been demonstrated to be required for AKT activation (Datta et al., 1999) . The phosphatidylinositol-dependent kinase, PDK-1 phosphorylates AKT at threonine-308 (Alessi et al., 1997a, b) . While PDK-1 requires the binding of PtdIns 3, 4, 5(P 3 ) to its pleckstrin homology domain as well as interaction with other protein kinases to efficiently phosphorylate AKT on threonine-308, PDK-1 is constitutively active and its activity is not enhanced by the presence of survival/growth factors (Balendran et al., 1999; Datta et al., 1999) . 3-Cl-AHPC had no effect on AKT threonine-308 phosphorylation in any of the cell lines but inhibited AKT serine-473 phosphorylation One can thus hypothesize that 3-Cl-AHPC inhibition of EGFR expression (the EGFR pathway being an important survival pathway) results in greater inhibition of serine-473-AKT phosphorylation through perhaps 3-Cl-AHPC inhibition of EGFR activation of ILK or other kinases and has a minimal effect on PDK-1 that is constitutively active. Recently, Ponzanelli et al. (2000) reported that exposure of the human promyelocytic leukemia cell line NB-4 to CD437/AHPN resulted in enhanced transient AKT phosphorylation within 1 h that returned to baseline within 4 h. This increased AKT phosphorylation was noted at the time of CD437/AHPN-mediated apoptosis in these cells. Tang et al. (2001) have demonstrated that AKT activation and AKT serine-473 phosphorylation can occur secondary to apoptosis induction. Whether the transient AKT phosphorylation noted by Ponzanelli et al. (2000) in the NB-4 cells is secondary to CD437/ AHPN or apoptosis induction is not clear. We have found that expression of a constitutively activated AKT in MDA-MB-468 and LNCaP cells results in the inhibition of 3-Cl-AHPC-mediated apoptosis, indicating that 3-Cl-AHPC inhibition of AKT activation is necessary for maximal 3-Cl-AHPC-mediated apoptosis. Several studies demonstrated that ILK can phosphorylate AKT on serine-473 with its subsequent activation (Delcommenne et al., 1998; Persad et al., 2000) . In addition, expression of a kinase inactive ILK results in the inhibition of AKT phosphorylation on the serine-473 residue as well as inhibition of AKT activity (Delcommenne et al., 1998) . ILK phosphorylation of AKT is PtdIns (3,4)P 2 and PtdIns (3,4,5)P 3 dependent in prostate carcinoma as well as other cell lines (Persad et al., 2000) . The lipid phosphatase PTEN dephosphorylates PI3-K-derived 3 0 -phosphorylated phosphatidylinositols. Expression of PTEN in PTEN-negative PC-3 prostate carcinoma cell line inhibits ILK-mediated AKT serine-473 phosphorylation and AKT activity (Persad et al., 2000) . 3-Cl-AHPC inhibits PI3-K activation with a subsequent decrease in PtdIns (3,4)P 2 and PtdIns (3,4,5)P 3 accumulation. ILK requires the binding of PtdIns (3,4)P 2 and PtdIns (3,4,5)P 3 to its pleckstrin domain for activation (Delcommenne et al., 1998) . Thus, 3-Cl-AHPC-mediated inhibition of PI3-K could also result in inhibition of ILK, AKT serine-473-phosphorylation and AKT activity. We found that 3-Cl-AHPC inhibited all of these steps in the prostate carcinoma cells. Exposure of DU145 cells to the PI3-K inhibitor LY 294002 inhibited ILK activity, AKT serine-473 phosphorylation and AKT activity suggesting a role for ILK in AKT serine-473 phosphorylation (data not shown). 3-Cl-AHPC inhibited AKT activity in the PTEN-negative PC-3 and LNCaP cells, indicating that 3-Cl-AHPC modulation of PTEN is not involved (Persad et al., 2000) .
AKT has been found to be constitutively active in a number of malignancies and its enhanced expression not only actively promotes the survival of these cells but also enhances their resistance to chemotherapy and radiation (Brognard et al., 2001) . We have found that overexpression of a constitutively active myristylated AKT results in resistance to 3-Cl-AHPC apoptosis. In addition, enhanced activation of PI3-K and AKT in NIH3T3 cells expressing the mutated Ras family member TC21
Dup 24À26 resulted in resistance to 3-Cl-AHPC-mediated apoptosis and 3-Cl-AHPC-mediated inhibition of AKT phosphoserine 473 levels (Rong et al., 2002 and data not shown). AKT enhances cell survival through the phosphorylation of a number of substrates. In response to apoptosis inducing stimuli, the proapoptotic protein Bad translocates to the mitochondria where it associates with and inactivates the antiapoptotic proteins Bcl-2 and Bcl-X L (Yang et al., 1995; Datta et al., 1997) . AKT-mediated phosphorylation of Bad on serine-136 sequesters Bad in the cytoplasm complexed with the 14-3-3 protein isoforms (Zha et al., 1996; Datta et al., 1999) . Similarly, AKT phosphorylation of FKHR1, results in its cytoplasmic sequestration bound to 14-3-3 proteins and its inability to induce the expression of genes that are critical for cell death, such as the Fas ligand gene . 3-Cl-AHPC inhibition of AKT activity results in the decrease in phosphoforkhead levels in the LNCaP, PC-3 and MDA-MB-468 cell lines. Interestingly, FKHR1 expression was not found in the DU145 cell line (data not shown).
We have previously demonstrated that exposure to CD437/AHPN induces apoptosis in both prostate and breast carcinoma cell lines (Shao et al., 1995; Li et al., 1996; Liang et al., 1999) . In order to assess whether inhibition of PI3-K and AKT would result in the induction of apoptosis in these cells, we utilized the specific PI3-K inhibitor LY 294002. The addition of LY 294002 to the cells resulted in the induction of apoptosis with the subsequent inhibition of ILK and AKT activities (data not shown); thus inhibition of PI3-K and AKT is sufficient to induce apoptosis in these cell lines. Similar results have been reported by Lin et al. (1999) utilizing the PI3-K inhibitor Wortmannin.
3-Cl-AHPC inhibition of AKT activity L Farhana et al CD437/AHPN has been reported to have a variety of effects in malignant cell lines and its induction of apoptosis in these cells may occur through a variety of mechanisms (Sun et al., 2000a) . This will likely be true for 3-Cl-AHPC as well 3-Cl-AHPC inhibition of PI3-K activity and AKT activity occurs prior to the onset of apoptosis, suggesting that the inhibition of the activities of these two enzymes may play a role in 3-Cl-AHPC induction of apoptosis in these cells.
The role of the RARs in 3-Cl-AHPC induction of apoptosis remains controversial. Sun et al. (2000b) have demonstrated that while CD437/AHPN-mediated differentiation of human head and neck squamous cell carcinoma cells requires RAR activation, its induction of apoptosis is RAR independent. However, Holmes et al. (2000) have demonstrated that CD437/AHPNmediated apoptosis in ovarian carcinoma cells requires RARg. Trans-retinoic acid, a potent activator of the RARs neither inhibits AKT activity nor induces apoptosis in these cells. 3-Cl-AHPC, which inhibits AKT and ILK activities and induces apoptosis in these cells does not activate RARs suggesting that RAR activation is not necessary.
Materials and methods
Materials/antibodies
3-Cl-AHPC was synthesized as described previously and stored at À801C in DMSO. DMEM-F12 medium, fetal bovine serum (FBS) and calf serum were purchased from Life Technologies Inc. (Grand Island, NY, USA). Anti-AKT phosphoserine-473, anti-AKT phosphothreonine-308 anti-AKT antibody and antiphosphoforkhead antibodies were purchased from Cell Signalling (Beverly, MA, USA). c-Cbl-1 antibodies were obtained from Transduction Laboratories (San Diego, CA, USA). EGFR antibody was obtained from Santa Cruz Inc. (Santa Cruz, CA, USA). Apoptosis was assessed using Apoptosis Elisa Kits obtained from Roche Diagnostic Laboratory (Indianapolis, IN, USA) as well as acridine orange staining as we have previously described (Li et al., 1996) .
Cell culture
The human prostate carcinoma cell lines, DU145, LNCaP and PC-3 and the breast carcinoma cell line MDA-MB-468 were maintained in medium supplemented with 5% FBS at 371C in a humidified incubator and a 95% air/5% CO 2 atmosphere.
Transfection
Cells were seeded into in six-well plates (2 Â 10 5 cells/well) and stably transfected with 0.5 mg of the pcDNA3 vector, mAktpcDNA3 vector or the EGFRcDNA vector per well using the LipofectAMINE Plus (Life Technologies, Inc., Carlsbad, CA, USA) as suggested by the manufacturer. The stable cells were selected with neomycine (600 mg/ml). The stable cells were treated with 1 mM 3-Cl-AHPC for 24 h and the extent of apoptosis ascertained by acridine orange.
Western blots
Cells were lysed with lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Triton X-100, 2.5 mM sodium orthovanadate, 10 ml/ml protease inhibitor cocktail (Sigma, St Louis, MO, USA), 1 mM PMSF and incubated for 20 min at 41C. The protein concentration was determined using the BioRad assay system (BioRad, Hercules, CA, USA). Total proteins were fractionated using SDS-PAGE and transferred onto nitrocellulose membrane. The membranes were blocked with 5% nonfat dried milk in 1 Â TBS buffer containing 0.1% Tween 20 and then incubated with appropriate primary antibody. Horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody and the protein bands were developed using the enhanced chemiluminesence detection system (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Quantification of Western blots was performed using laser densitometry and the results presented as the mean of three independent experiments with error bars representing standard errors.
Immunoprecipitation studies
Total protein (1000 mg) was incubated with 1 mg of appropriate antibody and 20 ml of protein G sepharose 4 fast flow bead (Amersham Pharmacia Biotech, Piscataway, NJ, USA) overnight at 41C, centrifuged and washed three times with TT buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.5% Tween 20) and twice with lysis buffer. Proteins were eluted with Laemmli sample buffer and fractionated using SDS-PAGE and as described for Western blots. Coimmunoprecipitations were performed as we have previously described .
AKT kinase assay
Cells were treated with 1 mM 3-Cl-AHPC for various time and lysed in a lysis buffer containing 25 mM HEPES (pH 7.5), 0.15 M NaCl, 5 mM MgCl 2 , 0.5 mM EGTA (pH 8.0), 20 mM bglycerophosphate, 0.5% Triton X-100, 10 mM NaF, 2 mM sodium orthovanadate, 5 mM dithiothreitol (DTT), 0.5 mM PMSF and 5 mg each of leupeptin, aprotinin and pepstatin per milliliter. Cell lysate proteins (1000 mg) were immunoprecipitated using anti-Akt polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and incubated with protein G sepharose 4 fast flow beads. The immunocomplexes were washed twice with lysis buffer and with kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT, 0.2 mM EGTA and 5 mM ATP). The kinase reaction was performed using histone H2B (Boehringer Mannheim, Indianapolis, IN, USA) as a substrate (0.1 mg/ml) in the presence of 10 mCi per reaction [g-P 32 ]ATP (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and incubated for 30 min at 301C. The reaction was stopped with Laemmli sample buffer and phosphorylation of histone H2B was analysed by 15% SDS-PAGE, followed by autoradiography.
ILK activity
Cells were lysed in 50 mM HEPES buffer (pH 7.5) containing 0.15 M NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 5 mM NaF, 1 mM sodium orthovanadate, 1.0 mM PMSF and 10 mg of the protease inhibitors, leupeptin, aprotinin and pepstatin per milliliter. Cell lysate proteins (1000 mg) were immunoprecipitated using anti-ILK polyclonal antibody (Upstate Biotechnology, New Placid, NY, USA) and incubated with protein G sepharose 4 fast flow beads overnight at 41C. The immunocomplexes were washed twice with lysis buffer and kinase buffer (50 mM HEPES (pH 7.0), 10 mM MgCl 2 , 10 mM MnCl 2 , 2 mM NaF, 1 mM sodium orthovanadate and 200 mM ATP). The kinase reaction was performed using myelin basic protein (5 mg) as described by Hannigan 3-Cl-AHPC inhibition of AKT activity L Farhana et al et al. (1996) . Proteins were electrophoresed on 12% SDS-PAGE and gels visualized by autoradiography.
PI3-K assay
PI3-K activity in the immunoprecipitations was determined utilizing the procedure of Auger et al. (1990) . 3-Cl-AHPCtreated and control cells were washed with ice-cold PBS and lysed with lysis buffer containing 20 mM Tris (pH 7.5), 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1% NP-40, 1 mM PMSF, 2.5 mM sodium orthovanadate and 10 mg/ml of aprotinin, leupeptin and pepstatin. Cell lysate proteins (1000 mg) were immunoprecipitated by anti-PI3-K mouse monoclonal antibody (BD Transduction, Lexington, KY, USA) and protein G sepharose fast flow bead. The immunocomplexes were washed three times with lysis buffer, twice with 100 mM Tris (pH 7.5), 5 mM LiCl and 0.1 mM sodium orthovanadate and twice with TNE buffer (10 mM Tris, pH 7.5), 150 mM NaCl 2 , 0.1 mM sodium orthovanadate, 5 mM EDTA. The washed immunocomplexes were suspended in 50 ml of TNE buffer and 20 mg of bovine brain extract and 10 ml of 100 mM MgCl 2 added. The reaction was started by the addition of 5 ml of reaction buffer (0.88 mM ATP, 10 mCi of [g-P 32 ]ATP and 10 mM MgCl 2 ) and incubated for 10 min at 371C. The reaction was stopped with 20 ml of 6 N HCl and the lipids extracted by addition of 160 ml of CHCL3/MeOH (1 : 1) to the samples. Labeled lipids were resolved on TLC plates (Silica Gel, Aldrich, St Louis, MO, USA) that have been precoated with 1% potassium oxalate and developed with chloroform : methanol : H 2 O : NH 4 OH (45 : 35 : 8.5 : 1.5). The plates were dried and autoradiographed.
Abbreviations AHPN/CD437, 6-[3-(1-adamantly)-4-hydroxyphenyl]-2-naphthalene carboxylic acid; 3-Cl-AHPC, 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid; EGFR, epidermal growth factor receptor; ILK, integrin-linked kinase; PI3-K, phosphatidylinositol 3 kinase; PtdIns (3,4)P 2 , phosphatidylinositol bisphosphate; PtdIns (3,4,5)P 3 , phosphatidylinositol triphosphate; FKHR, forkhead transcription factor.
